 BOSTON and ATLANTA, Mar. 25, 2022 PRNewswire -- Inhibikase Therapeutics, Inc. Nasdaq: IKT Inhibikase, a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinsons disease and related disorders, today announced that it will report financial results for the full year ended December 31, 2021 on Thursday, March 31, 2022, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. 